Skip to content

Telemedicine in Age-Related Macular Degeneration

Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age Related Macular Degeneration in Primary Care Settings.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04863391
Enrollment
1000
Registered
2021-04-28
Start date
2020-07-19
Completion date
2022-12-31
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Brief summary

This study seeks to evaluate a system for the automated early detection of Age-Related Macular Degeneration (AMD). AMD is a condition in which there is breakdown of the macula of the eye, the part of the retina that is responsible for sharp, central vision. We will take pictures of subjects' eyes using an automated camera. These photographs will be securely transmitted and and then analyzed by a computer program which has been developed in other studies. The outcome of the computer program analysis will be compared with human analysis of these same pictures. If the computer analysis is has good enough accuracy, then this computer system could be used for wide-scale screening for AMD.

Detailed description

iPredict,an AI and telemedicine based software which used individual's color fundus image for early diagnosis of AMD and predict if an individual is at risk of progression to late AMD. iPredict platform integrates the server-side programs (the image analysis and deep-learning modules for AMD severity screening and prediction) and local remote computer/mobile devices (for collecting patient data and images). DRS plus camera will be used in the doctor's office. The remote devices will upload images and data to the server to analyze and screen AMD automatically. The telemedicine platform has been developed for web-based platform. The automatic analysis will be performed on the server, and a report will be sent to the patient/remote devices with an individual's AMD stage as referable or non-referable AMD, and a risk prediction score of developing late AMD (within a minute), and further recommendations to visit a nearby ophthalmologist.

Interventions

DIAGNOSTIC_TESTReferrable versus Non Referral AMD diagnostic test

Artificial intelligence read reports Referrable versus Non Referral AMD

Sponsors

iHealthScreen Inc
CollaboratorINDUSTRY
The New York Eye & Ear Infirmary
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Subjects will be recruited if willing and able to comply with clinic visit and study-related procedures, and provide signed informed consent 2. Gender of Subjects: Both males and females will be invited to participate. 3. Age of Subjects: Patients will be over 50 years and older

Exclusion criteria

1. Unable to provide informed consent. 2. Other retinal degenerations and retinal vascular diseases such as diabetic retinopathy or macular edema, prior retinal surgery.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of identification of referable and non-referable AMD for early diagnosis of AMD2 yearsSensitivity of identification of referable and non-referable AMD for early diagnosis of AMD using the iPredict's AI-based AMD screening software utilizing color fundus imaging.
Specificity of identification of referable and non-referable AMD for early diagnosis of AMD using the iPredict's AI-based AMD screening software utilizing color fundus imaging.2 yearsUsing the gold standard (i.e., the ophthalmologist's grading), the sensitivity and specificity are calculated as: Sens=TP/(TP+FN) Spec=TN/(TN+FP) Where TP is the number of true positives (referable AMD subjects correctly classified), FN is the number of false negatives (referable AMD subjects incorrectly classified as non-referable), TN is the number of true negatives (non-referable subjects correctly classified), and FP is the number of false positives (non-referable AMD subjects incorrectly classified as referable AMD).

Countries

United States

Contacts

Primary ContactAlauddin Bhuiyan, Ph.D.
alauddin.bhuiyan@gmail.com718 926 9000
Backup ContactKaty Tai
ktai@nyee.edu2129794251

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026